Canada Markets closed

Iterum Therapeutics plc (ITRM)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.3300-0.0041 (-1.23%)
At close: 04:00PM EST
0.3300 0.00 (0.00%)
After hours: 07:23PM EST

Iterum Therapeutics plc

Harcourt Centre
Block 2, Floor 3 Harcourt Street
Dublin 2
Ireland
353 1 903 8920
https://www.iterumtx.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees7

Key Executives

NameTitlePayExercisedYear Born
Mr. Corey N. FishmanPres, CEO & Director1.07MN/A1965
Ms. Judith M. MatthewsChief Financial Officer606.14kN/A1970
Dr. Michael W. Dunne M.D.Strategic Advisor & Director561.68kN/A1960
Mr. Tom Loughman Ph.D.Sr. VP of Technical OperationsN/AN/AN/A
Ms. Louise BarrettSr. VP of Legal Affairs & Sec.N/AN/AN/A
Dr. Sailaja Puttagunta M.D.Chief Medical OfficerN/AN/A1969
Dr. Steven I. Aronin M.D.Sr. VP & Head of Clinical Devel.N/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was founded in 2015 and is headquartered in Dublin, Ireland.

Corporate Governance

Iterum Therapeutics plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.